Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Biotech M&A Wave Positions SBIO for Growth

BY | ETF Database
10:17 am ET 01/29/26 | 16 VIEWS
The biotech M&A market is heating up as pharmaceutical companies confront a looming patent cliff that will strip $200 billion to $250 billion in branded medicine sales by 2032, according to an ING report published in January. As patents expire on blockbuster drugs, cheaper generic versions can enter the market and slash revenue for the original drugmakers.The research projects both the number of acquisitions and the total dollars spent on deals will each increase 15% in 2026. Approximately 520 transactions totaling $230 billion expected across the sector. The shift creates opportunities for investors in funds holding mid-cap biotech companies with drugs in advanced clinical trials, according to the ING analysis. Big Pharma is hunting for companies with drugs already proven effective in patients rather than betting on early-stage research. Some 80% of expected deals in 2026 focused on acquiring these more advanced treatments that can quickly move toward FDA approval and generate revenue. The ALPS Medical Breakthroughs ETF (SBIO B-) holds the type of companies pharmaceutical giants are targeting, according to ETF Database. The fund requires holdings to have at least one drug in Phase II or Phase III FDA clinical trials. This means each company has already demonstrated its treatment works in humans and is moving toward potential approval. SBIO’s 87 holdings collectively have 205 drugs in Phase II trials and 118 in Phase III, according to the fund’s factsheet.Pharma M&A Targets in SBIO PortfolioAn Equity Insider report published Monday highlighted diabetes and kidney disease as major chronic disease markets. The report notes 589 million people globally live with diabetes while 850 million are affected by kidney disease. SBIO holds companies developing treatments for these conditions, which are exactly what pharmaceutical companies need to replace their expiring drugs. The fund’s diabetes-focused holdings include MannKind Corporation (MNKD), which develops inhaled insulin therapies. The company reported fourth-quarter revenue exceeding $100 million, according to the Equity Insider report. Viking Therapeutics, Inc. (VKTX) and Structure Therapeutics, Inc. (GPCR), which represent 2.2% and 3.4% of the portfolio respectively. Both companies are developing obesity treatments. Travere Therapeutics, Inc. (TVTX), a 1.7% holding, focuses on rare kidney diseases, addressing the other major chronic disease area highlighted in the report. The fund’s treatment focus breakdown shows rare and orphan diseases comprise 32.72% of holdings. Meanwhile DREEN conditions (dermatology, respiratory, eye, ear, and neurology) account for 29.67%, according to the fund’s factsheet. Cancer represents 21.46% and cardiology and hematology make up 16.14%. SBIO has gained 58.5% over the past year, topping all ALPS ETF products in performance for 2025, according to ETF Database. The fund ended December with $141.9 million in assets under management and carries a 0.50% expense ratio. Read more: ALPS ETFs in Biotech and Commodities Lead 2025 Gains The ING report notes reduced uncertainty in the U.S. market following pricing agreements with branded pharmaceutical companies, while expected Federal Reserve rate cuts in 2026 will lower the cost of capital for acquisitions. For more news, information, and analysis, visit the ETF Building Blocks Content Hub. VettaFi LLC (“VettaFi”) is the index provider for SBIO, for which it receives an index licensing fee. However, SBIO is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of SBIO.

More Commentary

Top Performing Leveraged/Inverse ETFs: 01/25/2026
BY | ETF Database
7:21 am ET 01/29/26 | 87 VIEWS
High-Yield Prospects: January 28 Edition
BY | ETF Database
01/28/2026 | 238 VIEWS
Buy on the Dip Prospects: January 21 Edition
BY | ETF Database
01/21/2026 | 776 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.